medium may produce false positive results (11). In this report, we describe two modifications of the original Bethesda assay which result Antibodies against factor VIII coagulant activity can appear in in markedly increased specificity and allowed us to diagnose and monihaemophiliacs who are treated with factor VIII preparations but also tor the presence of factor VIII :C inhibitors, spontaneously in non-haemophiliacs. The Bethesda assay is the most commonly used method to detect these antibodies, but it lacks specificity especially in the lower range resulting in unreliable data.
Introduction *
The development of factor VUI-inhibitors may complicate substitu tion treatment in haemophiliacs. Consequently, these patients are in danger of uncontrolled bleeding and need long-term treatment with expensive factor VIII preparations to induce immunotolerance.
Early reports concerning the incidence of inhibitors were controver sial (1 ), but recent prospective studies confirmed their presence in the blood between 5% and 20% of haemophiliacs (2-8). Moreover, inhibi tors were also detected in healthy individuals (9) .
The reasons for the wide variation in results are manifold and in clude the type of concentrate used, the severity of haemophilia, ex-
Original Bethesda Assay

Materials and Methods
Plasma Preparation
Nine volumes of blood were drawn into one volume of 0.13 M sodium citrate using Vacutainers (Becton-Dickinson, New Yersey, USA). Plasma was prepared by centrifugation for 15 inin at 4300 X g and 4° C, then stored at -70° C until required.
Normal pooled plasma (N-pool) was prepared by mixing plasma from at least 50 healthy blood donors aged 18-65 years selected to represent all blood groups and sexes equally.
Buffering was achieved by adding solid imidazole (Merck, Darmstadt, Germany) to yield a concentration of 0.1 M then adjusting the pH by slowly adding 1 N HC1 while constantly stirring at 4° C.
Factor VIII: C Assay
Factor VIII¡Coagulant activity (FVIII:C activity) was measured in a one stage APTT-based clotting assay (12) using PTT(a)-reagent (Stago, Asniere, France), Immu nodepleted factor VIII deficient plasma (Organon Teknika, Durham, USA) and N-pool as a 100% reference.
Clotting times were recorded with a KC-10 coagulometer (Amelung, Lemgo, Germany). posure time as well as ethnic origin, family history and age at the start of substitution therapy. However, both over-and underestimation might originate from the use of the Bethesda assay used to detect in hibitors. There is no agreed cut-off value for the Bethesda Units (BU/ml) to discriminate between inhibitor-positive and negative pa tients which range from zero to 0.8 BU/ml (2-10) which indicates that the assay lacked specificity especially at the lower range of activity,
We recently drew attention to this anomaly and reported that in sufficient buffering and variable protein concentration in the assay Correspondence to: Dr. Bert Verbruggen, Central Laboratory for Haema tology, Geert Grooteplein 8, N-6525 GA Nijmegen, The Netherlands -FAX Number: +3180568408 Anti-FVIII:C activity was measured with the Bethesda assay according to Kasper (13) .
N-pool was mixed with either an equal volume of patient plasma (test mix ture) or with 0.1 M imidazole buffer pH 1A (control mixture). After 2 h of in cubation at 37° C, the relative percentage FVIII: C activity of the test mixture compared to the control mixture (residual FVIII: C activity) was determined. The FVIII :C activity in the test mixture was corrected for intrinsic residual FVIII: C activity (e. g. at mild or sub-haemophilia).
One Bethesda Unit (BU) was defined as that amount of inhibitor that resulted in 50% residual FVIII: C activity.
The inhibitor activity was read in BU/ml from a semilogarilhmic plot repre senting the correlation between residual FVIII :C activity (logarithmic) and in hibitor activity (linear) (13) . When the residual FVIII:C activity of undiluted sample was below 25%, retesting was performed by diluting with 0.1 M imi dazole buffer pH 7.4 until a residual FVIII :C activity of 25% to 75% was obtained. Ail data are the means of 5 determinations ± the standard deviation.
Modified Bethesda Assay
Test plasma as well as immunodepleted factor VIII deficient control plasma (pool of at least 20 individuals, Organon Teknika, Durham, USA) were mixed with equal volumes of 0.1 M imidazole buffered N-pool pH 7.4 and incubated for 2 h at 37° C. The FVIII :C activity was measured in both mixtures and corrected for the intrinsic activity. The inhibitor activity was quantified as described for the original Bethesda assay. If necessary, plasma samples were diluted before testing with immunodepleted factor VIII deficient plasma.
In addition, samples with inhibitor activity of more than 2 BU/ml were also assayed by empirically determining the plasma concentration which gives 50% inhibition. Therefore, a number of dilutions were tested and the residual concentration that gave 50% residual FVIII: C activity was estimated by extra polation and the reciprocal value of it equals the inhibitor activity in BU/ml. FVIII:C activity of at least 4 assays within the range of 25% to 75% were plotted versus the plasma dilution semilogarithmically or arithmetically. The The remaining FVIII;C activity was defined as the activity obtained after incubation compared to the preincubation value.
All pH measurements were carried out with a PHM-92-meter (Radiometer, Copenhagen, Denmark).
Patients
Samples of plasma were obtained from 4 groups of patients: 32 haemophil iacs without history of inhibitor: 10 with less than 1 percent FVIII; C activity (group la) and 22 with activity between I and 20% (group lb), 5 patients with a history of factor VIII inhibitor but free of medication and symptoms of inhibi tor at the time of sampling (group 11), 6 patients who were being treated for an inhibitor at the time of sampling and still had evidence of inhibitor-activity such as bleeding complications and decreased recovery after factor VIII substitution (group III) and 8 patients with high levels of inhibitor activity in the initial stage of treatment with immunosuppressives (group IV). Column A; Plasma samples were assayed in two different dilutions and inhibitor activities were calculated from the correlation graph and multiplied with the dilution factor. Column B: Plasma samples were assayed in at least 4 different dilutions and the activity was estimated by finding the dilution giving 50% inhibition. Fig, 1) . FVIII; C inactivation increased with increasing pH but was only marginal at physiological pH. FVIII: C inactivation in mixtures with half the protein concentration was higher at all pH levels compared to mixtures of N-pool and deficient plasma.
Results
pH Changes and FVIII: C Inactivation
ma mixtures rising to approximately 17% in mixtures with saline. This relation between pH and FVIII: C inactivation was further investigated in mixtures of buffered N-pool at various pH levels and factor VIII deficient plasma or saline (
Patients 4
No inhibitor activity was detected with the modified method in the samples obtained from the 32 haemophiliacs of groups la and lb whereas with the original assay inhibitor activities ranging from 0.5 to 0.9 BU/ml were found ( Table 2) .
Plasma from the patients in group II showed no activity in the modi fied assay whereas with the original assay the activity ranged from 0.1 to 0.7 BU/ml. With both methods increased inhibitor activities were detected in all samples from patients in group III, but all except one sample showed lower activities (0.2-0.4 BU) with the modified method. All samples from patients in group IV showed high activities with both methods, However, the calculated inhibitor activity in the latter varied with the degree of plasma dilution (Table 3, column A) . In plasma of patients with type I inhibitor (samples 1-5) the activity increased with decreasing dilution whereas the empirically deter mined data were in between (Table 3, column B) . In contrast, plasma of patients of type II inhibitor (6 » 7) showed maximal activity at the highest dilution and the empirically determined inhibitor activities were even higher. 
Residual FVIII: C activity
Discussion
The Bethesda assay is the most widely used method for detection of FVIII: C inhibitors. FVIII: C inactivation in both a test mixture (normal plasma/patient plasma) and a control mixture (normal plasma/0.1 M degree of dilution. This appears to be due to the aberrant kinetics of facimidazole buffer pH 7.4) is measured and expressed in inhibitor ac-tor VIII and its inhibitor which is not linearly correlated but is complex tivity.
as was implied but not specifically noted by Kasper (13) , reported by hibitor activity that was absent at the time of sampling gave identical results. Samples from patients that were receiving immunosuppressive medication and who still had clinical evidence that an inhibitor was present, showed elevated activities with both methods but the activities with the modified method were lower than with the original method.
These data indicate that the specificity of the modified method was improved while the sensitivity remained unchanged.
The specificity for detection of high inhibitor activities was similar with both methods but the calculated activities were dependent on the We observed a significant increase in pH and FVIII: C inactivation Biggs (14) and confirmed by our findings. Data above the hypothetical in mixtures of N-pool and inhibitor-free factor VIII deficient plasma, linear curve between 50% and 100% residual FVIII: C activity of each In experiments with imidazole-buffered N-pool (pH ranging from individual sample will result in an underestimation of inhibitor activity 7.2 to 8.3) we showed that FVIII: C inactivation increases with pH and whereas data below the curve will result in the converse which explains that reduced protein concentration leads to further inactivation of FVIII : C activity. These phenomena may be the source of falsely posi tive inhibitor activities in patient samples when assayed with the origi nal Bethesda assay. We therefore introduced two substitutions in order to circumvent these imperfections.
Firstly, the N-pool plasma used in test and control mixture was buffered with 0.1 M imidazole to stabilize.the pH at 7.4. Secondly, the imidazole buffer in the control mixture was replaced by immunodepleted factor VIII deficient plasma to attain comparable protein concentrations in both mixtures. As a result, FVIII : C inactivation was virtually identical in both control and test mixtures being marginal in both.
Plasma-samples of 32 haemophiliacs which were free of inhibitor activity yielded values of O.OBU/ml with the modified method, whereas activities between 0.5 and 0.9 BU/ml were obtained with the original method. Plasma-samples from patients with a history,of in-the anomalies shown in Table 3 , Quantification of high inhibitor ac tivities will be erroneous unless a concentration-independent assay is devised.
If there is a need for more uniform quantification, e. g. follow-up of treatment, it may be more relevant to estimate empirically the plasma dilution that gives 50% inhibition.
In conclusion, we present two modifications of the original Bethes da assay which improve the specificity and reliability and suggest a method for the optimal quantification of high inhibitor activities.
We suggest to define this method the "Nijmegen assay" for detection and quantification of FVIII : C inhibitors.
